Join VP of Clinical Services Joe Solien, PharmD, BCPP, BCGP this Thursday June 27th for SIB in Dementia: Deriving Drug Therapy Recommendations from Case Reports - you won't want to miss learning best practices for coping with this behavior in patients with dementia! Register here: https://hubs.ly/Q02D1gN00 #OPPC #hospice #pharmacy #webinar
OnePoint Patient Care’s Post
More Relevant Posts
-
The FDA has made a pivotal move in its approach to Alzheimer's drug development, suggesting that amyloid reduction can now serve as a surrogate endpoint for predicting clinical benefits. This comes after years of debate about the relationship between amyloid reduction and cognitive health improvements in Alzheimer's patients. With new guidelines released, the FDA is paving the way for more innovative treatments following the controversial approval of Aduhelm and the recent focus on Eisai and Biogen’s Leqembi. It's a significant moment that could accelerate the availability of new therapies for those in the early stages of Alzheimer's disease. #FDA #AmyloidReduction https://lnkd.in/eiagmFTM
To view or add a comment, sign in
-
Speranza Therapeutics, a leading neuromodulation company located in South Florida has a high demand for providers in Florida, Ohio, Texas, Connecticut, Pennsylvania, Tennessee, New York, and Georgia that can prescribe, place, and monitor the S.T. Genesis. The S.T. Genesis is a neuromodulation device that is FDA cleared and is used for the dramatic reduction of opioid related withdrawal symptoms once the opioid has been discontinued. We’ve joined forces with one of the leading speciality pharmacies in the country to make it easier for providers to supply this device to patients in need. This is an incredible opportunity to expand your practice and answer the massive call from the patient population. If you’d like to learn more about this breakthrough device, contact us at info@speranzatherapeutics.com to speak to a representative. Speranza Therapeutics: A new way to fight addiction. #addictionrecovery #addictionsupport #fightaddiction #substanceusedisorder #endthestigma #opioidaddiction #drugaddiction #recovery
To view or add a comment, sign in
-
Coming to the end of #LewyBodyDementiaAwarenessMonth, but the work continues. Cognition Therapeutics, Inc. is developing orally delivered CT1812 with a #neuroprotective mechanism that has potential as a treatment for #DLB. Learn more about our Phase2 SHIMMER #clinicaltrial here: https://lnkd.in/g7whCeeQ
To view or add a comment, sign in
-
Biopharma, MindBio Therapeutics, recently completed a phase 2a clinical trial investigating the use of a take-home microdosing regimen for depression. In a recent interview with Clinical Leader, MindBio CEO, Justin Hanka, breaks down the details of the trial and explains how hallucinogenics could be key to more effectively treating depression. “Ultimately, our goal is to bring MB22001 through late-stage clinical development and regulatory approval, paving the way for a new paradigm in mental health treatment,” Hanka says. “One where patients can safely and effectively manage their conditions from the comfort of their own homes.” Source: https://hubs.li/Q02CHtF-0 #Microdosing #MindBioTherapeutics #Depression #Hallucinogenics #ClinicalTrials #Phase2aClinicalTrial #DepressionResearch #MentalHealth #PsychedelicMedicine
To view or add a comment, sign in
-
From the AMMG E-Journal, Quest Diagnostics Launches Alzheimer’s Blood Test for Consumers: https://lnkd.in/eK5MxMJt. "Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer’s protein which can appear years before dementia symptoms arise.The $399 test, called AD-Detect, uses the same technology as a blood test the company launched for use by doctors in early 2022. “One of the advantages of having an amyloid test is that it lets you know, potentially years in advance of even being symptomatic, that you are at risk for Alzheimer’s,” said Dr. Michael Racke, Quest’s medical director of neurology. The announcement follows full U.S. regulatory approval earlier this month of Leqembi, a drug from Eisai and partner Biogen that removes amyloid from the brain and has been shown to slow the advance of Alzheimer’s in early-stage patients. A similar treatment from Eli Lilly called Donanemab is under review by the U.S. Food and Drug Administration." READ MORE HERE: https://lnkd.in/eK5MxMJt #AlzheimersBloodTest #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences #AMMGSpring2024
To view or add a comment, sign in
-
Meet the company behind the S.T. Genesis and learn how we’re changing the way people overcome addiction. Speranza Therapeutics distributes and clinically supports innovative drugs and medical devices requiring FDA approval or clearance. We prioritize patients whose chronic illnesses and debilitating conditions are not being effectively addressed. Our mission statement is to remove the inherent challenges in delivering treatment to patients in need through proven, clinically effective therapeutics and technology. That is why Speranza Therapeutics has teamed up with a major pharmacy company to get the S.T. Genesis to people who need it most. The S.T. Genesis is a game-changer when it comes to addiction. Find out how at our website. Join the fight against addiction with Speranza Therapeutics #recoveryispossible #addictionrecovery #addictionsupport #addictionhelp #opioidaddiction #endthestigma #mentalhealthsupport #detoxwithoutfear
Speranza Therapeutics | LinkedIn
linkedin.com
To view or add a comment, sign in
-
This week, Eli Lilly and Company’s donanemab received unanimous support from an FDA advisory committee in favor of its efficacy and positive benefit-risk profile for patients with mild cognitive impairment and mild dementia. The committee praised donanemab as an innovative therapy and as industry stakeholders, we applaud this development, signifying a positive step towards an effective treatment for Alzheimer’s. We remain committed to collaborating with industry leaders to achieve a common goal - to change the lives of millions suffering from Alzheimer's by striving to deliver early diagnoses to access effective treatments. To learn about donanemab's FDA approval, read more here: https://lnkd.in/gnVypxSb #Alzheimers #DigitalBiomarkers #Altoida #DigitalHealth #MedTech #DigitalHealth #HealthTech #HealthcareInnovation
Alzheimer’s drug with modest benefits wins backing of FDA advisers
nature.com
To view or add a comment, sign in
-
From the AMMG E-Journal, Quest Diagnostics Launches Alzheimer’s Blood Test for Consumers: https://bit.ly/3TDtpm4. "Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer’s protein which can appear years before dementia symptoms arise.The $399 test, called AD-Detect, uses the same technology as a blood test the company launched for use by doctors in early 2022. “One of the advantages of having an amyloid test is that it lets you know, potentially years in advance of even being symptomatic, that you are at risk for Alzheimer’s,” said Dr. Michael Racke, Quest’s medical director of neurology. The announcement follows full U.S. regulatory approval earlier this month of Leqembi, a drug from Eisai and partner Biogen that removes amyloid from the brain and has been shown to slow the advance of Alzheimer’s in early-stage patients. A similar treatment from Eli Lilly called Donanemab is under review by the U.S. Food and Drug Administration." READ MORE HERE: https://bit.ly/3TDtpm4 #AlzheimersBloodTest #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences #AMMGSpring2024
To view or add a comment, sign in
-
1. Eli Lilly's Alzheimer's drug, donanemab (branded as Kisunla), has been approved by Japan's health ministry. 2. This approval follows the previous approval of Eisai and Biogen's drug, Leqembi, in September of last year. 3. Japan is the second major market for Kisunla, after the United States. 4. Over 4.6 million people in Japan are currently living with dementia, a number expected to rise due to an aging population. 5. By 2035, individuals aged over 65 will make up 32.3% of Japan's population. 6. Kisunla, like Leqembi, targets the beta-amyloid protein in the brain and has shown to slow cognitive decline by 29% in clinical trials. 7. The drug carries significant safety warnings for brain swelling and bleeding, similar to Leqembi. 8. Kisunla has a finite dosing regimen, allowing patients to discontinue treatment once amyloid plaques are no longer detected.
Eli Lilly's Alzheimer's drug approved in Japan — Reuters
apple.news
To view or add a comment, sign in
2,256 followers